Back to Top Skip to main content

Turning on lifesaving trials at Madigan Army Medical Center

Image of soldier in front of a laptop Janell Cain, a clinical research coordinator at Madigan with the Infectious Disease Clinical Research Program, records the informed consent forms signed by a patient receiving treatment for COVID-19 in the intensive care unit from Madigan’s Virtual Critical Care Center on April 14. Communicating with the patient and nurses via the video equipment, Cain gains the necessary consent to enroll a patient in a study of remdesivir as a COVID-19 treatment without expending personal protective equipment, or exposing anyone to the patient unnecessarily. The IDCRP is a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. (Lt. Col. (Dr.) Christopher Colombo)

Recommended Content:

Coronavirus

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. – Madigan Army Medical Center, on Joint Base Lewis-McChord, Wash., has been a hotbed for biomedical research for years, highlighted by patented innovations and award winning presentations at national and international scientific meetings.

In response to the COVID-19 global pandemic, Madigan is currently supporting nine research protocols designed to address gaps in knowledge including clinical characteristics of the COVID-19 illness, the impact of nutrition on COVID-19 risk, and the clinical value of convalescent plasma, in which a patient with severe disease is given plasma from someone who has recovered from COVID-19 and therefore has antibodies to it in their blood, to name a few.

Possibly the most notable clinical trial for COVID-19 treatment involves remdesivir, an investigational, broad-spectrum antiviral drug that has shown some promise, in animal trials, in both Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, and is the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

When the trial began in February, Dr. Anthony Fauci, the director of NIAID and a member of the U.S. Coronavirus Task Force said, “We urgently need a safe and effective treatment for COVID-19. Although remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes. A randomized, placebo-controlled trial is the gold standard for determining if an experimental treatment can benefit patients.”

Madigan is one of 68 international trial sites among 47 in the U.S. and 21 in Europe and Asia. The first enrollee was at the University of Nebraska Medical Center/Nebraska Medicine, in February; he had been on a cruise ship that saw a number of infections.

The initiation of the trial can is described here: https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins.

Within two months of initiation, the clinical trial of remdesivir has produced encouraging results.

In a statement issued on April 29, the NIAID reported, “Preliminary results indicate that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group (p=0.059).”

This trial is managed at Madigan by the Infectious Disease Clinical Research Program, a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. The IDCRP conducts clinical research that focuses on reducing the impact of infectious diseases relevant to the DoD.

For more information about the IDCRP, visit: https://www.idcrp.org/about-us.

The IDCRP has a broad research portfolio, including an ongoing study looking at the efficacy of different formulations of the flu vaccine. When COVID-19 emerged, the IDCRP pivoted to get this research up and running in a very short period of time. As an established IDCRP site, Madigan was identified as one of the military treatment facilities eligible for participation in the NIAID trial.

“Because they are so active and such a squared-away group, they were able to help get this trial off the ground,” said Lt. Col. (Dr.) Christopher Colombo, principal investigator for the COVID-19 trial and the director of Virtual Health and Telecritical Care at Madigan.

Madigan has strong and adaptive biomedical research capabilities that are facilitated by its Department of Clinical Investigation.

“The Department of Clinical Investigation, Dr. Rick Burney (DCI’s chief) and Dr. (Silvija) Salai (the human subject protection administrator), have been fantastic in supporting and expediting this and balancing making sure that everything is still done dress-right-dress according to regulatory, safety and scientific integrity filings, but it is going quite a bit faster than usual, because of the situation that we're in,” noted Lt. Col. Colombo.

Madigan is one of five DoD sites that has enrolled patients in the study so far and is already ramping up for its next phase. Investigators stress that these are early days of evaluation for this trial. Given the high transmissibility and global spread of this virus, research has moved quickly.

“It's a placebo controlled trial, so the patients are randomized. We don't know who's getting what. They either get placebo or remdesivir,” Lt. Col. Colombo said.

NIH requirements for inclusion in the trial comprise the need for hospitalization for documented COVID-19 infection and either an abnormal chest x-ray or the requirement for supplemental oxygen or mechanical ventilation. Trial participation is limited to adults.

Participants in the treatment group get 200 milligrams (mg) of remdesivir injected on the first day they are in the study and 100 mg each day of their hospitalization, up to 10 days total. Those in the placebo group receive the same amount of what looks like remdesivir but contains only inactive ingredients.

This means the trial is administered to patients currently being treated in the hospital, though some have since improved and gone home. They return to the hospital periodically for monitoring.

Dr. Rhonda Colombo, an infectious diseases physician who works in support of the IDCRP at Madigan, praised the contributions of patients who volunteered to participate in this and other ongoing clinical research trials.

“Without willing and engaged study participants, clinical research is not possible. At Madigan, we are incredibly fortunate to be part of a community that values clinical research. Our research team is humbled by the generosity and commitment of the people who volunteer to participate in our studies,” said Dr. Colombo.

With drug safety and long-term effects always in mind, the team is not yet ready to draw conclusions, but is optimistic about the data so far.

Susan Chambers, the clinical operations manager for the IDCRP at Madigan echoed that appreciation for the high value that Madigan, and the JBLM community place on research, noting that it is the providers and nurses on the inpatient units who directly support research within their care of patients.

“We are incredibly proud to have the opportunity to offer access to cutting-edge research for our Active Duty personnel and DoD beneficiaries. Our success would not be possible without the support of Madigan Commander Col. Thomas Bundt and the committed inpatient clinical care teams at Madigan,” said Chambers.

On Friday, May 1, the U.S. Food and Drug Administration gave remdesivir emergency use authorization to treat COVID-19.

The NIAID expects to share additional data soon, as well as next steps.

“We managed to get meaningful research turned on, very quickly. Other sites in the Department of Defense, are kind of looking at Madigan like you guys are knocking it out of the park, keep going,” said Lt. Col. Colombo. “I think it's something that's cool in terms of how we're responding to COVID in a positive way and making some good come of this.”

Disclaimer: Re-published content may be edited for length and clarity.  Read original post.

You also may be interested in...

Genetic sequence data for SARS-CoV-2

Infographic
6/5/2020
Infographic describing how DoD was able to conduct genome sequencing on the COVID-19 virus

Genetic sequence data for SARS-CoV-2, the virus that causes #COVID19, plays a vital role in force health protection efforts within the DoD. To jumpstart sequencing efforts, the Armed Forces Health Surveillance Branch's Global Emerging Infections Surveillance and Response applied a collaborative approach to sequencing capabilities. Resulting sequence data will provide critical information about transmission patterns, track diagnostic effectiveness, and guide the development and evaluation of medical countermeasures.

Recommended Content:

Armed Forces Health Surveillance Branch | Coronavirus | Global Emerging Infections Surveillance

DoD Establishes Collaborative Virus Genetic Sequencing Capability for COVID-19

Article
6/5/2020
Image of two scientists in masks looking at a computer monitor

COVID-19 sequencing process will provide military commanders and other DoD leadership with critical information to guide force health protection decision-making.

Recommended Content:

Armed Forces Health Surveillance Branch | Coronavirus | Global Emerging Infections Surveillance

Putting talent to work

Article
6/5/2020
Three military personnel wearing masks

One seamstress took it upon herself to create face coverings for her colleagues.

Recommended Content:

Coronavirus

WRNMMC Operates Drive-Up Immunization Clinic

Article
6/3/2020
Nurse giving a shot to a girl; both wearing masks

Parents and others (are encouraged) to maintain their immunization health during COVID-19.

Recommended Content:

Coronavirus | Immunization Healthcare

TRICARE Reserve Select (TRS) Health Plan Reinstatement During COVID-19 National Emergency

Fact Sheet
6/2/2020

Fact sheet explaining that explaining that TRICARE Reserve Select beneficiaries now have five months to reinstate terminated coverage after their last paid-through date before a 12-month lockout period will apply.

Recommended Content:

Coronavirus | TRICARE Changes and You

The 150th Security Forces Squadron supports NM COVID-19 response effort

Article
5/29/2020
Group of military personnel posting for a picture

The 150th Security Forces Squadron and the New Mexico National Guard’s Joint Task Force COVID-19 are providing support that may not otherwise be available to New Mexico communities and their citizens.

Recommended Content:

Coronavirus

Building Your Mental Health Through Resiliency

Article
5/29/2020
Soldier walking through a maze

Being able to think about things from a different perspective is critical.

Recommended Content:

Coronavirus

DoD experts address COVID-19 effects on mental health

Article
5/29/2020
Image of soldier wearing a mask

As the world adjusts to a new normal, here’s how to keep mentally healthy.

Recommended Content:

Coronavirus

DoD launches effort to collect COVID-19 convalescent plasma

Article
5/29/2020
Image of man wearing mask and giving blood

Plasma donations needed in the fight against COVID-19

Recommended Content:

Coronavirus

DOD COVID-19 Survivor Gives Shoutout to Doctors, Plasma Donors

Article
5/29/2020
Image of soldier sitting on a bench with flowers and a balloon

Bright was the first person in the District of Columbia to receive convalescent plasma.

Recommended Content:

Coronavirus

MHS Minute: Military Leading the Charge on COVID-19 Research

Video
5/28/2020
Image of MHS Minute Carousel

The military continues to serve on the front lines of research and treatment in response to the COVID-19 pandemic. Tune in to the MHS Minute to learn more.

Recommended Content:

Coronavirus

'Home sweet home' leaves a sour taste for some quarantine-weary

Article
5/28/2020
Family playing board game

Mental health professionals offer tips on managing during uncertain times

Recommended Content:

Coronavirus | Mental Health Care | Mental Wellness

USU Aids Health Care Providers, Community in Pandemic

Article
5/27/2020
Image of two healthcare workers looking sad

USU’s Center for the Study of Traumatic Stress provides fact sheets as a resource for providers and the community.

Recommended Content:

Coronavirus | Public Health

Regional Health Command-Atlantic staff treat COVID-19 patients at NJ hospital

Article
5/27/2020
Three people in scrubs around a patient on a hospital bed

The officers assigned to the program were selected because they have medical specialties typically used in military forward surgical teams.

Recommended Content:

Coronavirus

Force Health Protection Guidance (Supplement 9) -Department of Defense Guidance for Deployment and Redeployment of Individuals and Units during the Novel Coronavirus Disease 2019 Pandemic

Publication
5/26/2020

This memorandum provides force health protection (FHP) deployment and redeployment guidance for Service members (including Reserve Component (RC) and National Guard members in a title 10 or title 32 duty status) and DoD civilian employees deploying within and outside the United States during the COVID-19 pandemic, consistent with references (a) and (b).

Recommended Content:

Coronavirus
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 10

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.